This is a working overview of peptide research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-17 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Years pass and Annie contacts Demon about publishing his book. Demon knows that she is expecting a baby and drives to Lee County to meet her instead. After seeing that Lewis has taken Annie to the hospital to give birth, Demon visits Betsy, Dick and June. Skipping a retirement party for Coach, Demon fears the traumatic memories that returning to Lee County would surface. He asks Betsy about Angus’ love life, knowing she shares things with Betsy she doesn’t with him. Coyly, the old woman tells him to ask her himself, saying she only has one man in mind. Visiting Angus the next day, who is preparing to sell Coach's old house, Demon begins to understand they have always had feelings for each other. The book ends with Angus and Demon driving toward the ocean together, his hand tenderly touching the back of her neck.
== L == LALLS – Low-angle laser light scattering LC-MS – Liquid chromatography-mass spectrometry LEED – Low-energy electron diffraction LEEM – Low-energy electron microscopy LEIS – Low-energy ion scattering LIBS – Laser induced breakdown spectroscopy LOES – Laser optical emission spectroscopy LS – Light (Raman) scattering
== Interactions == Chlorprothixene may increase the plasma-level of concomitantly given lithium. In order to avoid lithium intoxication, lithium plasma levels should be monitored closely. If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side effects of opioids considerably. Avoid the concomitant use of chlorprothixene and tramadol (Ultram). Seizures may be encountered with this combination. Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbiturates. Choose particular low doses of these drugs. Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe constipation, even ileus and glaucoma .
Sources: en.wikipedia.org
I Am Maximus ridden by Paul Townend wins the 2024 Grand National. Sunak condemns Iran's attack against Israel and says the UK is working to stabilise the situation. 14 April Sunak confirms that RAF fighter jets shot down "a number of drones" fired at Israel by Iran. Richard Lee, whose daughter Katrice Lee disappeared near a British military base in Paderborn, Germany, in 1981, says he will hand back his Army medals in protest at how the case was handled. Lawyers representing around 250 survivors of the Manchester Arena bombing confirm plans to take legal action against MI5. Charities supporting asylum seekers announce plans to launch legal challenges to moving people to Rwanda once legislation declaring it a safe country is passed in the coming days. The Duke of Kent confirms he is stepping down as Colonel of the Scots Guards after 50 years, and handing the role over to the Duke of Edinburgh. The UK experiences its warmest temperature of 2024 so far, with 21.8 °C recorded in the village of Writtle, near Chelmsford, Essex. 15 April Sunak urges "all sides" to "show restraint" after Iran's attack on Israel. A report by the Resolution Foundation calls for changes to Universal Credit to take into account an aging population with health problems. 16 April Figures show the rate of UK unemployment rose to 4.2% between December 2023 and March 2024, its highest level for six months. EasyJet cancels all flights to and from Tel Aviv for the whole of the summer, citing safety concerns following Iran's drone and missile attack on Israel.
== Structural studies == As of late 2007, 13 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1AY4, PDB: 1AY5, PDB: 1AY8, PDB: 2AY1, PDB: 2AY2, PDB: 2AY3, PDB: 2AY4, PDB: 2AY5, PDB: 2AY6, PDB: 2AY7, PDB: 2AY8, PDB: 2AY9, and PDB: 3TAT.
Soon after Crick's death, there have been allegations about him having used LSD when he came to the idea of the helix structure of the DNA. While he almost certainly did use LSD, it is unlikely that he did so as early as 1953. In the late 1960s he was given LSD by Henry Todd who met Crick through his girlfriend who had modelled for Crick's wife.
== History == In the 1990s, clinafloxacin showed promise as a novel, broad-spectrum fluoroquinolone antibiotic. However, further clinical trials raised serious concerns regarding its safety in humans, citing dangerously low blood sugar, drug-induced light sensitivity, and multiple drug-drug interactions.
Sources: en.wikipedia.org
. The americium-241 and curium-242 isotopes also were produced by irradiating plutonium in a nuclear reactor. The latter element was named after Marie Curie and her husband Pierre who are noted for discovering radium and for their work in radioactivity. Bombarding curium-242 with α-particles resulted in an isotope of californium 245Cf in 1950, and a similar procedure yielded berkelium-243 from americium-241 in 1949. The new elements were named after Berkeley, California, by analogy with its lanthanide homologue terbium, which was named after the village of Ytterby in Sweden. In 1945, B. B. Cunningham obtained the first bulk chemical compound of a transplutonium element, namely americium hydroxide. Over the few years, milligram quantities of americium and microgram amounts of curium were accumulated that allowed production of isotopes of berkelium and californium. Sizeable amounts of these elements were produced in 1958, and the first californium compound (0.3 μg of CfOCl) was obtained in 1960 by B. B. Cunningham and J. C. Wallmann. Einsteinium and fermium were identified in 1952–1953 in the fallout from the "Ivy Mike" nuclear test (1 November 1952), the first successful test of a hydrogen bomb. Instantaneous exposure of uranium-238 to a large neutron flux resulting from the explosion produced heavy isotopes of uranium, which underwent a series of beta decays to nuclides such as einsteinium-253 and fermium-255.
The causes of autism are a subject of scientific research, but understanding of the etiology of autism is incomplete. It is influenced by a complex interplay of genetic, epigenetic, prenatal, perinatal, and environmental factors. Genetics play a major role, with heritability estimates ranging from 60–90%. De novo mutations—including copy number variations and gene-disrupting mutations—contribute to approximately 30–40% of cases. However, most autism cases involve complex interactions among multiple inherited genetic variants, many of which are still unknown. Epigenetic mechanisms, such as DNA methylation and genomic imprinting, also influence gene expression and susceptibility, often interacting with environmental exposures. In rare cases, autism has been associated with agents that cause birth defects. Prenatal risk factors include advanced parental age, maternal metabolic or autoimmune disorders, infections, and prenatal stress, while perinatal risks involve preterm birth, low birth weight, and birth complications. Postnatal mechanisms have been proposed, including immune dysregulation, gastrointestinal abnormalities, oxidative stress, and neural circuit differences, though these remain largely unproven and are the focus of ongoing research. Some Neanderthal-derived genetic variants may influence susceptibility. Current high-quality evidence shows no causal link between prenatal use of paracetamol and autism. Overwhelming scientific evidence shows no causal association between thiomersal and vaccines, including the measles-mumps-rubella (MMR) vaccine, and autism.
Colombia topped their first-round group at the 1991 Copa América in Chile, beating Brazil 2–0 along the way, but lost all three matches in the four-team final round to finish fourth. Maturana returned in 1993 to oversee qualification for the 1994 FIFA World Cup. With Valderrama as captain, Colombia reached the semi-finals of the 1993 Copa América, eliminating Uruguay on penalties in the quarter-finals before losing 6–5 on penalties to Argentina after a goalless semi-final in Guayaquil. Adolfo Valencia scored the only goal in a 1–0 win over the hosts Ecuador in the third-place match in Portoviejo. Colombia went through the 1994 qualifying group unbeaten, winning four and drawing two of six matches and conceding twice. The campaign closed on 5 September 1993 at the Estadio Monumental in Buenos Aires, where a 5–0 victory over Argentina — two goals each for Rincón and Faustino Asprilla, and a fifth from Adolfo Valencia — sealed qualification and consigned the 1990 finalists to a play-off. The result made Colombia among the most widely tipped sides for the finals; Pelé named them his favourites for the title.
== Pharmacokinetics == In infected individuals, the elimination half-life of artesunate is about 0.22 hours. Its active metabolite, DHA, has a slightly longer half-life of 0.34 hours. Overall, the average half-life ranges from 0.5 to 1.5 hours. Because of its short half-life, its use in malaria prevention is limited. DHA is metabolized to an inactive metabolite by the liver enzymes CYP2B6, CYP2C19, and CYP3A4.
=== Lima Group === With Castillo taking a more pro-Venezuela stance, many thought that Peru would leave the Lima Group, a consortium of countries with the goal of aiding the Venezuelan opposition. Starting 6 August 2021, Venezuelan and Cuban state media started claiming that Peru had left the Lima Group. While foreign media had announced Peru's exit, there was no word from the Peruvian government, which left many confused. Furthermore, Luis Arce, the President of Bolivia, celebrated Peru's supposed departure from the Lima Group. There was still no word from the Castillo Administration. However, Peru's departure from the Lima Group had been seemingly confirmed by Free Peru's General Secretary, Vladimir Cerrón. As a result, domestic media and Congress was left unsure on whether Peru had left the organization or not. Eventually, members of Congress sent forward a motion to confirm Peru's status in the Lima Group. After a while, Prime Minister Bellido confirmed that Peru had not left the Lima Group, claiming that the issue had not been formally discussed. However, Bellido also mentioned that the Foreign Ministry was evaluating Peru's status in the Lima Group. As of 20 September 2021, the permanent representative of Peru to the OAS has stated that the Lima Group "does not exist, because it has completed its cycle." Later, the Vice Foreign Minister pointed out "The Lima Group is a mechanism, it is not an international organization, and therefore mechanisms work when they need to work.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.